Frazier Life Sciences

The firm operates coordinated venture and public equity strategies. The venture arm builds companies around early-stage assets, typically co-leading Series A rounds. The public equity team, running a long-only pool, then evaluates those same companies for crossover investments, PIPEs, or follow-on public-market purchases, providing capital continuity and reducing reliance on external public investors.

Company creation is central to the venture strategy. Since 2015, the firm has created over 25 companies by founding or co-founding entities around licensed academic technology or corporate spinouts, often working with co-investors such as 5AM Ventures and DCVC. Radionetics Oncology, co-created with 5AM and Crinetics in 2021, is one example.

The public equity strategy is a long-only, evergreen vehicle targeting publicly traded small- and mid-cap biopharmaceutical companies and private crossover rounds. It can take concentrated positions, serve as a sole investor in PIPEs as it did for Krystal Biotech in 2018, and maintain holdings through commercialization and FDA approval.

Jamie Topper serves as Managing Partner. The firm lists additional General Partners dedicated to venture, company creation, and public portfolio management, though it does not disclose a full partnership roster. Operating advisors and senior advisors provide scientific and operational support to portfolio companies but are not employees of the firm.

Frazier Life Sciences operates as a dedicated biotechnology and therapeutics investment platform. It is a separate entity from Frazier Healthcare Partners, which historically invested across healthcare services and therapeutics before spinning out or separating its life sciences activities into the current firm structure.

The venture strategy raises closed-end funds. Its most recent vehicle closed in July 2025 at $1.3 billion, oversubscribed (per the firm, July 2025). These funds invest in company creation, Series A rounds, and follow-on private financings.

Yes. The public equity strategy frequently supports portfolio companies through commercialization. With Krystal Biotech, for example, the public team invested pre-FDA approval and participated in a subsequent PIPE to fund the commercial launch of Vyjuvek for dystrophic epidermolysis bullosa.